Conore Steuer News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Conore Steuer. Real-time updates on events, politics, business and more.

Should NSCLC Patients Receive Immunotherapy 'Indefinitely'?

September 15, 2023

Most long-term responders to immunotherapy continue taking the drugs after 2 years. But data show long-term use likely offers no survival benefit.

Schleswig Holstein United States Santa Monica University Of Pennsylvania Jonathanw Goldman Conore Steuer

Source: medscape.com

Daiichi Sankyo: Patritumab Deruxtecan Continues to Show Promising Clinical Activity in Patients Across Subtypes of Metastatic Breast or Lung Cancer

June 3, 2022

Data from a phase 1/2 trial in patients with several subtypes of HER3 expressing metastatic breast cancer featured as oral presentation at ASCO First presentation of phase 1 data from a cohort

United States Masashi Kawase Iane Krop Daiichi Sankyo Daiichi Sankyo Europe Gmb Patritumab Deruxtecan

Source: finanznachrichten.de

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Conore Steuer News Today

Should NSCLC Patients Receive Immunotherapy 'Indefinitely'?

Daiichi Sankyo: Patritumab Deruxtecan Continues to Show Promising Clinical Activity in Patients Across Subtypes of Metastatic Breast or Lung Cancer

Explore More Categories